Is the business good?
How good a business is ALNY?
Alnylam Pharmaceuticals, Inc. keeps 14% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
14%
Operating margin · Biotechnology median −72% · 12 months to Q4 2025
- Cash conversion
- 1.71×
Cash conversion · every dollar of reported profit arrived as cash, and more
- R&D as % of revenue
- 36%
R&D as % of revenue
- Gross margin
- 82%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −168% |
| FY2021 | −84% |
| FY2022 | −76% |
| FY2023 | −15% |
| FY2024 | −7.9% |
| FY2025 | 14% |
Details›
- Gross margin12 months to Q4 2025
- 82%
- Operating margin12 months to Q4 2025
- 14%
- Net margin12 months to Q4 2025
- 7.3%
- Free cash flow margin
- 13%
- R&D as % of revenue
- 36%
- Revenue, trailing twelve months
- $3.71B
- Free cash flow, trailing twelve months
- $465M
- Net income, trailing twelve months
- $272M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Biotechnology
Ranks #57 of 145 by Smart Score